Purdue Pharma launches Hysingla ER

STAMFORD, Conn. — Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydrocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection — though abuse of the drug through intravenous, intranasal and oral routes is still possible.

 

“Acetaminophen toxicity and the misuse and abuse of opioids are real concerns among clinicians treating people with chronic pain,” said Bob Twillman, Ph.D., executive director at the American Academy of Pain Management. “The availability of a hydrocodone product with abuse-deterrent properties that does not contain acetaminophen gives healthcare professionals and chronic pain patients an important new treatment option.”

 

Hysingla ER received FDA approval in November 2014 and is available in 20-, 30-, 40-, 60-, 80-, 100- and 120-mg dosage strengths. Purdue is offering a patient trial card and copay support programs for eligible patients.